Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27554 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dose-optimised recombinant human thrombopoietin eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study).
EClinicalMedicine
September 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospi
Background: Recombinant human thrombopoietin (rhTPO) at a fixed dose of 300 U/kg/day for 2 weeks has demonstrated good efficacy and safety in adults with immune thrombocytopenia (ITP). This trial aimed to develop a flexible and personalized rhTPO regimen that ensures efficacy and safety beyond previous fixed dose, with eltrombopag as an active comparator.
Methods: The TE-ITP trial was conducted in 12 centers across China.
Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis.
Clin Lymphoma Myeloma Leuk
July 2025
H. Lee Moffitt Cancer Center, Tampa, FL.
Background: Thrombocytopenia in myelodysplastic syndromes (MDS) is associated with bleeding complications, transfusion dependence, and reduced quality of life. While platelet transfusions remain standard care, they carry limitations including short durability, alloimmunization, and infection risk. Thrombopoietin receptor agonists (TPO-RAs), such as eltrombopagand romiplostim, have emerged as potential alternatives, but their efficacy and safety remain incompletely defined.
View Article and Find Full Text PDFUnderstanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.
Curr Oncol
August 2025
Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Chemotherapy-induced thrombocytopenia (CIT) is a common yet underrecognized complication of systemic chemotherapy, particularly in gastrointestinal (GI) cancers. Despite progress in targeted and immune-based therapies, platinum-based and fluoropyrimidine regimens, especially oxaliplatin-containing protocols, remain standard in GI cancer treatment and are linked to high rates of CIT. This complication often leads to treatment delays, dose reductions, and elevated bleeding risk.
View Article and Find Full Text PDFCase Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemia.
Front Pediatr
August 2025
Pediatric Hematology and Oncology Department and Foundation for the Biomedical Research, and Biomedical Network Research Center for Rare Diseases (CIBERER), Pediatric University Hospital Niño Jesús, Madrid, Spain.
Fanconi anemia (FA) constitutes the most common of the inherited bone marrow failure syndromes, a group of rare heterogeneous disorders characterized by cytopenia, predisposition to hematologic and solid malignancies and diverse clinical features. Currently, the only available hematopoietic curative treatment for bone marrow failure is an allogeneic hematopoietic stem cell transplantation (HSCT), although gene therapy has demonstrated evidence of efficacy and substantially reduced toxicity. It has been demonstrated that eltrombopag stimulates trilineage hematopoiesis in aplastic anemia, and preclinical studies suggest it promotes DNA repair in FA hematopoietic stem cells (HSCs).
View Article and Find Full Text PDFArterial Thrombosis in Patients with Primary Immune Thrombocytopenia: A Nationwide Study.
Turk J Haematol
August 2025
Trakya University Faculty of Medicine, Department of Hematology, Edirne, Türkiye.
Introduction: Primary immune thrombocytopenia (pITP) is an acquired bleeding disorder related with mainly decreased number of platelets due to destruction or impaired production of platelets. Clinical presentation of pITP can be multifaceted, and thrombotic events may rarely manifest. Thrombosis can develop with treatment or during the untreated period.
View Article and Find Full Text PDF